Idéal Investisseur Galteron Galteron
Français English
CAC 40 : Market open
8 281,80 pts
-0.84%


Last updated : 17/11/2026 - 11h50
🏠 Home   ➤    Stock news

Cellectis shares fall 64.5% over the quarter and remain below their MM20

The Paris-listed biotech resumes its decline after the plunge that followed its nine-month results. The stock is trading in a bearish Paris market, while the company undergoes a strategic refocus toward in vivo genome editing.


Cellectis shares fall 64.5% over the quarter and remain below their MM20

A stock below its three moving averages, close to the €0.94 support

The Cellectis share loses 2.95% intraday, to €0.97, for a 7.66% decline over one week. The price is now below its MM20 (a gap of 7.57%), after the stock had rebounded in early November before running into resistance at €1.35.

The €0.94 support is about 3% from the current price: this is the level sellers have within reach.

The decline extends a very difficult quarter, with a 64.29% loss over three months, and the MACD remains in negative territory despite an improving histogram. The CAC 40 is down 0.99% at the same time, while the Nasdaq closed down 2.49% on Monday, amid a correction in artificial intelligence-related stocks.

Following nine-month results, cash runway announced through the second half of 2028

On November 13, Cellectis published nine-month results marked by a net loss of $101.1 million, compared with $41.3 million a year earlier. Among the risks cited on this occasion were the discontinuation of the lasme-cel and eti-cel clinical programs and a workforce reduction of up to 70% over 2026-2027.

On the pipeline side, the group expects preliminary data for HEAL-101 in the second half of 2027, following a Phase 1 trial in China, and its cash is expected to fund development through the second half of 2028.

Cellectis is listed in Paris (ordinary shares, eligible for the PEA French equity savings plan) and on the Nasdaq as ADSs, which explains why US trading sessions regularly weigh on the Paris line: the Nasdaq fell 2.49% on Monday.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: T3 2026
Key reported figures
  • Revenue: 5,4 millions de dollars
  • Quarterly revenue: 5,4 millions de dollars
  • Net income: -61,5 millions de dollars

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours